Dear FAPI Community,

SOFIE is gearing up for an exciting spring season on the FAPI front. Our Gilroy, CA, site, now joins Totowa, NJ, as a production site for GMP grade [18F]-FAPI-74 for clinical research.  We have begun the process to start production of [18F]-FAPI-74 at our Romeoville, IL, site, and three additional manufacturing sites for FAPI-74 are planned over the next twelve months.  These are concrete, meaningful steps toward enhancing access to FAPI for our academic and industry partners. Dr. Sharmila Dorbala at Brigham and Women’s Hospital – Harvard Medical School is one such valued partner, with SOFIE recently supporting her study on Imaging Fibroblast Activation in Myocardial Diseases.

I am also pleased to share SOFIE’s support of Avacta’s therapeutic studies targeting FAP. [18F]-FAPI-74 is serving as a complementary diagnostic in Avacta’s Phase 1 trial for AVA6000, a chemotherapy drug, with the goal of helping better identify FAP expression in the tumor microenvironment.

The annual SNMMI meeting is just around the corner, taking place June 8-11 in Toronto, Canada.  This year we are co-sponsoring with GE HealthCare a satellite symposium, “Driving Molecular Imaging Innovation with ‘FAPI’”, on Sunday, June 9, 6:30-8:30 pm.  Please remember to stop by the SOFIE Booth (1116) to speak to a member of the FAPI team with any questions you may have. Partners, please reach out if you’d like to schedule a meeting at SNMMI. We hope to see you there!

Finally, in SOFIE’s continuing efforts to educate the larger clinical community about FAPI, on May 30, I presented a webinar on the “Current state of FAP Targeting Radioligands”.  If you missed it, it’s available for viewing here

As always, thank you for reading our newsletter. We sincerely appreciate your input on how this can be a better resource for the FAPI community.

Sherly Mosessian, Ph.D.

Sherly Mosessian, Ph.D., Chief Scientific Officer



For more details on the FAPI symposium agenda, click here.


FAPI Pipeline Spring 2024


Each newsletter will feature recent FAPI publications.

[68Ga]Ga-FAPI-46 PET/CT for penile cancer - a feasibility study
68Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy
A Systematic Review on the Diagnostic Value of Fibroblast Activation Protein Inhibitor PET/CT in Genitourinary Cancers


Join us in advancing the frontier of molecular imaging through the FAPI Outreach Program

SOFIE is continuing to accept applications for our FAPI Outreach Program. This program aims to raise awareness and foster collaboration in the field of molecular imaging, specifically focusing on Fibroblast Activation Protein Inhibitor (FAPI) studies. This program seeks to engage with healthcare professionals, researchers, and the broader community to share knowledge, advancements, and the potential impact of FAPI in diagnostic and therapeutic applications.

*GE Healthcare licensed products and regions will be ready for new application reviews in April.

Copyright 2024 SOFIE CO. / ITHERANOSTICS INC. (21000 Atlantic Blvd. Suite 730  Dulles, VA  20166) all rights reserved.  The text or images in the newsletter may not be copied or distributed without prior permission of SOFIE. The SOFIE logo is a registered trademark of SOFIE CO. / ITHERANOSTICS INC., in the United States and/or other countries. All other trademarks referenced herein are the property of their respective owners. You have received this mail because you have subscribed for a newsletter at www.sofie.com or because you are an existing client or partner of SOFIE. If you no longer wish to receive these emails, click here to opt out.  This newsletter is meant to serve as an informational document as a service to our customers. The content or material provided is for informational purposes only and should and should not be construed as medical, legal, financial, investment, or other professional advice or opinion. SOFIE does not offer personalized medical advice or patient-specific treatment advice.